Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Upstream Bio, Inc.NASDAQ: UPB
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 35.6% from a year ago
Cash & equivalents stood at $96.72M at the end of Q1 FY2026, up 35.6% from a year earlier and down 4.8% from the prior quarter. Over 3 fiscal years it compounded at +81.3% a year.
Context
- Cash & equivalents amounted to 30.4% of total assets at the end of Q1 FY2026, up 14.8 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +35.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 101.58M USD
- Year-over-year change
- -68.8%
- 3-year CAGR
- +81.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 101.58M | -68.8% |
| FY2024 | 2024-12-31 | 325.89M | +1161.5% |
| FY2023 | 2023-12-31 | 25.83M | +51.5% |
| FY2022 | 2022-12-31 | 17.05M | — |
Cash & Equivalents vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +35.6% is the 3rd highest of 10, against a peer median of +6.4%.
- Cash & equivalents amounts to 30.4% of total assets for UPB, versus a peer median of 27.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $544.59M USD | +124.0% | +89.5% | 93.3% | |
| Mar 2026 | $500.22M USD | +154.5% | +18.1% | 66.9% | |
| Sep 2026 | €282.73M EUR | -14.1% | +21.7% | 95.8% | |
| Sep 2026 | $240.1M USD | +6.6% | +53.6% | 30.5% | |
| Mar 2026 | $228.36M USD | -13.3% | -43.5% | 21.9% | |
| Mar 2026 | $134.7M USD | +6.2% | -33.3% | 17.8% | |
| Mar 2026 | $130.89M USD | -15.0% | +22.0% | 27.7% | |
| Jun 2026 | $121.19M USD | +6.4% | -17.9% | 12.5% | |
UPBUpstream Bio, Inc. | Mar 2026 | $96.72M USD | +35.6% | +81.3% | 30.4% |
| Sep 2026 | $82.73M USD | +27.5% | +35.0% | 7.5% | |
| Peer median (excluding UPB) | — | +6.4% | +21.7% | 27.7% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.